Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine

Abstract Background Lasmiditan (LTN) is a selective 5-HT1F receptor agonist for the acute treatment of migraine in adults. We present detailed safety findings from the placebo-controlled, double-blind Phase 3 study, of LTN treatment across 4 attacks (CENTURION). Methods Patients were randomized 1:1:...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: C Tassorelli, S Bragg, JH Krege, EG Doty, PA Ardayfio, D Ruff, SA Dowsett, T Schwedt
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
R
Acceso en línea:https://doaj.org/article/55ad02cbed234cf4a58c92860dd14765
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares